The rapidly growing field of functional, molecular and structural bio-imaging is providing an extraordinary new opportunity to overcome the limits of invasive liver biopsy and introduce a "digital biopsy" fo...The rapidly growing field of functional, molecular and structural bio-imaging is providing an extraordinary new opportunity to overcome the limits of invasive liver biopsy and introduce a "digital biopsy" for in vivo study of liver pathophysiology. To foster the application of bio-imaging in clinical and translational research, there is a need to standardize the methods of both acquisition and the storage of the bio-images of the liver. It can be hoped that the combination of digital, liquid and histologic liver biopsies will provide an innovative synergistic tri-dimensional approach to identifying new aetiologies, diagnostic and prognostic biomarkers and therapeutic targets for the optimization of personalized therapy of liver diseases and liver cancer. A group of experts of different disciplines(Special Interest Group for Personalized Hepatology of the Italian Association for the Study of the Liver, Institute for Biostructures and Bio-imaging of the National Research Council and Bio-banking and Biomolecular Resources Research Infrastructure) discussed criteria, methods and guidelines for facilitating the requisite application of data collection. This manuscript provides a multi-Author review of the issue with special focus on fatty liver.展开更多
Several chronic disorders including type 2 diabetes(T2D),obesity,heart disease and cancer are preceded by a state of chronic lowgrade inflammation.Biomarkers for the early assessment of chronic disorders encompass acu...Several chronic disorders including type 2 diabetes(T2D),obesity,heart disease and cancer are preceded by a state of chronic lowgrade inflammation.Biomarkers for the early assessment of chronic disorders encompass acute phase proteins(APP),cytokines and chemokines,pro-inflammatory enzymes,lipids and oxidative stress mediators.These substances enter saliva through the blood flow and,in some cases。展开更多
Non-alcoholic fatty liver disease(NAFLD)is classically defined as the hepatic manifestation of metabolic syndrome(1).Histologically,NAFLD covers a range of conditions,spanning from simple steatosis to non-alcoholic st...Non-alcoholic fatty liver disease(NAFLD)is classically defined as the hepatic manifestation of metabolic syndrome(1).Histologically,NAFLD covers a range of conditions,spanning from simple steatosis to non-alcoholic steatohepatitis(NASH)and cirrhosis(2).At present,NAFLD is the most frequent chronic liver disease seen in clinical practice in high-income countries,as it affects nearly 30%of adults in the general population,up to 70%of patients with type 2 diabetes(T2DM)and almost all patients with obesity(2).展开更多
Nonalcoholic fatty liver disease(NAFLD)is the major contributor to the global burden of chronic liver diseases and ranges from simple and reversible steatosis to nonalcoholic steatohepatitis(NASH),which may progress i...Nonalcoholic fatty liver disease(NAFLD)is the major contributor to the global burden of chronic liver diseases and ranges from simple and reversible steatosis to nonalcoholic steatohepatitis(NASH),which may progress into cirrhosis and hepatocellular carcinoma(HCC).HCC represents the most common liver cancer,and it is a leading cause of death worldwide with an increasing trend for the future.Due to late diagnosis,non-responsiveness to systemic therapy,and high cancer heterogeneity,the treatment of this malignancy is challenging.To date,liver biopsy and ultrasound(US)are the gold standard procedures for HCC diagnosis and surveillance,although they are not suitable for mass screening.Therefore,it is impelling to find new,less invasive diagnostic strategies able to detect HCC at an early stage as well as monitor tumor progression and recurrence.Common and rare inherited variations that boost the switching from NASH to liver cancer may help to predict tumor onset.Furthermore,epigenetic changes which reflect intertumoral heterogeneity occur early in tumorigenesis and are highly stable under pathologic conditions.The severity of hepatic injuries can be detected through the analysis of cell circulating tumor DNAs(ctDNAs),microRNAs(miRNAs),and noncoding RNAs(ncRNAs),which are involved in several pathological processes that feature cancer,including cell growth,survival,and differentiation,thus representing appealing biomarkers for HCC.Therefore,this review discusses the current options for HCC surveillance,focusing on the role of genetic and epigenetic biomarkers as new strategies to refine HCC management.展开更多
Nonalcoholic fatty liver disease(NAFLD)is becoming the leading cause of liver disease worldwide,and the prevalence is still increasing,especially during the developmental age(1-3).NAFLD is defined in the presence of i...Nonalcoholic fatty liver disease(NAFLD)is becoming the leading cause of liver disease worldwide,and the prevalence is still increasing,especially during the developmental age(1-3).NAFLD is defined in the presence of increased hepatic fat content not explained by at risk alcohol intake,and is epidemiologically associated with obesity,insulin resistance and metabolic disorders.展开更多
基金Supported by the Italian Ministry of Health Project,No.RF-2010-2314264
文摘The rapidly growing field of functional, molecular and structural bio-imaging is providing an extraordinary new opportunity to overcome the limits of invasive liver biopsy and introduce a "digital biopsy" for in vivo study of liver pathophysiology. To foster the application of bio-imaging in clinical and translational research, there is a need to standardize the methods of both acquisition and the storage of the bio-images of the liver. It can be hoped that the combination of digital, liquid and histologic liver biopsies will provide an innovative synergistic tri-dimensional approach to identifying new aetiologies, diagnostic and prognostic biomarkers and therapeutic targets for the optimization of personalized therapy of liver diseases and liver cancer. A group of experts of different disciplines(Special Interest Group for Personalized Hepatology of the Italian Association for the Study of the Liver, Institute for Biostructures and Bio-imaging of the National Research Council and Bio-banking and Biomolecular Resources Research Infrastructure) discussed criteria, methods and guidelines for facilitating the requisite application of data collection. This manuscript provides a multi-Author review of the issue with special focus on fatty liver.
基金(partially)supported by the Italian Ministry of Health(Ricerca Corrente 2022-Fondazione IRCCS CàGranda Ospedale Maggiore Policlinico)by the Italian Ministry of Health(Ricerca Finalizzata-GR-2019-12370172)。
文摘Several chronic disorders including type 2 diabetes(T2D),obesity,heart disease and cancer are preceded by a state of chronic lowgrade inflammation.Biomarkers for the early assessment of chronic disorders encompass acute phase proteins(APP),cytokines and chemokines,pro-inflammatory enzymes,lipids and oxidative stress mediators.These substances enter saliva through the blood flow and,in some cases。
文摘Non-alcoholic fatty liver disease(NAFLD)is classically defined as the hepatic manifestation of metabolic syndrome(1).Histologically,NAFLD covers a range of conditions,spanning from simple steatosis to non-alcoholic steatohepatitis(NASH)and cirrhosis(2).At present,NAFLD is the most frequent chronic liver disease seen in clinical practice in high-income countries,as it affects nearly 30%of adults in the general population,up to 70%of patients with type 2 diabetes(T2DM)and almost all patients with obesity(2).
基金supported by Italian Ministry of Health(Ricerca Corrente 2022,Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico,Milano)Ricerca Finalizzata Ministero della Salute GR-2019-12370172.
文摘Nonalcoholic fatty liver disease(NAFLD)is the major contributor to the global burden of chronic liver diseases and ranges from simple and reversible steatosis to nonalcoholic steatohepatitis(NASH),which may progress into cirrhosis and hepatocellular carcinoma(HCC).HCC represents the most common liver cancer,and it is a leading cause of death worldwide with an increasing trend for the future.Due to late diagnosis,non-responsiveness to systemic therapy,and high cancer heterogeneity,the treatment of this malignancy is challenging.To date,liver biopsy and ultrasound(US)are the gold standard procedures for HCC diagnosis and surveillance,although they are not suitable for mass screening.Therefore,it is impelling to find new,less invasive diagnostic strategies able to detect HCC at an early stage as well as monitor tumor progression and recurrence.Common and rare inherited variations that boost the switching from NASH to liver cancer may help to predict tumor onset.Furthermore,epigenetic changes which reflect intertumoral heterogeneity occur early in tumorigenesis and are highly stable under pathologic conditions.The severity of hepatic injuries can be detected through the analysis of cell circulating tumor DNAs(ctDNAs),microRNAs(miRNAs),and noncoding RNAs(ncRNAs),which are involved in several pathological processes that feature cancer,including cell growth,survival,and differentiation,thus representing appealing biomarkers for HCC.Therefore,this review discusses the current options for HCC surveillance,focusing on the role of genetic and epigenetic biomarkers as new strategies to refine HCC management.
文摘Nonalcoholic fatty liver disease(NAFLD)is becoming the leading cause of liver disease worldwide,and the prevalence is still increasing,especially during the developmental age(1-3).NAFLD is defined in the presence of increased hepatic fat content not explained by at risk alcohol intake,and is epidemiologically associated with obesity,insulin resistance and metabolic disorders.
